...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current oncology reports. >Targeting the Androgen Receptor in Breast Cancer
【24h】

Targeting the Androgen Receptor in Breast Cancer

机译：针对乳腺癌中的雄激素受体

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The androgen receptor (AR) is expressed in the majority of breast cancer and across the three main breast cancer subtypes. Historically, the oncogenic role of AR has best been described in molecular apocrine breast cancers, an estrogen receptor (ER)-/AR+ subtype which has a steroid response signature similar to that in the ER-positive breast cancer. The signalling effect of AR is likely to be different across breast cancer subtypes, and particularly important is its interaction with ER signalling. Despite the high frequency of AR expression in breast cancer, it is still not a standard clinical practice to use AR antagonists as therapy. Older trials of AR-directed therapies in breast cancer have had generally been disappointing. More recently, more potent, next-generation, AR-directed therapies have been developed in the context of prostate cancer. Here, we will review the emerging literature dissecting the role of AR signalling in a context-dependent manner in breast cancer and the renewed interest and wave of clinical trials targeting the AR in breast cancer.
机译：雄激素受体（AR）在大多数乳腺癌和三种主要的乳腺癌亚型中表达。从历史上看，AR的致癌作用已在分子顶泌性乳腺癌中得到了最好的描述，这是一种雌激素受体（ER）-/ AR +亚型，其类固醇反应特征类似于ER阳性乳腺癌。在乳腺癌亚型中，AR的信号传导作用可能有所不同，尤其重要的是它与ER信号传导的相互作用。尽管在乳腺癌中AR表达的频率很高，但是使用AR拮抗剂作为疗法仍然不是标准的临床实践。以往，针对AR的乳腺癌治疗方法的较早试验普遍令人失望。最近，在前列腺癌的背景下，已经开发出了更有效的下一代AR导向疗法。在这里，我们将回顾新兴的文献，剖析AR信号以上下文相关的方式在乳腺癌中的作用，以及针对AR在乳腺癌中的临床研究的新兴趣和热潮。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号